Navigation Links
PTC Therapeutics to Showcase Breadth of Pipeline at Upcoming R&D Day
Date:10/19/2013

SOUTH PLAINFIELD, N.J., Oct. 18, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it will hold its first R&D Day on Friday, October 25, 2013 from 8:30 a.m. to 12:00 p.m. ET at the Four Seasons Hotel in New York City. Members of PTC's senior management and research teams will provide a corporate update and in-depth reviews of the company's scientific platforms and R&D programs.

(Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

A live webcast of the event will be available on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com. The presentation will be archived for 2 weeks following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection. 

About PTC Therapeutics, Inc.       
PTC is biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and form the basis for collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website www.ptcbio.com  

Forward Looking State
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS Asserts its Position in Difficult Environment 2
(Date:12/20/2014)... Parker & Sons, Inc. a focused ... experience in contractor services announces reaching a milestone by ... homeowners of Arizona. Parker and Sons is comprised of ... that make customer service the number one priority. The ... started with one service vehicle and has since grown ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with the ... to the wayside until Christmas and the New Year are ... and that burning desire to just escape it all and ... to Telluride with a no-fuss, affordable package. Montrose Days Inn ... resort, and ensure that all accommodations are met. Plus, everyone ...
(Date:12/19/2014)... 2014 Energy Textiles is excited ... available. Celliant, the world’s leading responsive textile, can ... , There are a number of benefits to ... oxygenation and balanced body temperature; which can lead ... relief; enhanced athletic performance; and overall wellness. In ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 SuperCloset raises ... SuperClone Rooms. SuperCloset continues to offer indoor growers the ... one of the new SuperClone Rooms with the award ... and turnkey indoor hydroponic grow room setup. , The ... world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... December 20, 2014 An evening dress is ... a lady’s closet. Discount-Dress.com, a distinguished dresses retailer, has unveiled ... beautiful dresses in this great shopping platform. Customers can ... the staff's hard work, Discount-Dress.com has been accepted and praised ... faster and easier shopping stage for clients. In order to ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2
... also Establishes New Site Leadership Team at Cambridge ... Continuing the,solidification of its role as the global ... that Andrew D. Skibo has joined the company,as ... a 19-year,veteran of the company, has been promoted ...
... Philadelphia, PA, December 20, 2007 For U.S. veterans ... health functioning are associated with an increased risk of ... of the journal General Hospital Psychiatry. , "Our findings ... for mental health functioning as a risk factor and ...
... tests, so have advanced disease , , THURSDAY, Dec. 20 ... have health insurance are more likely to die because ... so are typically diagnosed with advanced disease, a new ... finding proffers strong evidence that differences in cancer survival ...
... WOODCLIFF LAKE, N.J., Dec. 20 Par,Pharmaceutical Companies, Inc. ... and Exchange Commission (SEC) its Form 10-Q for the ... for this period had been,delayed due to the work ... periods, which were filed earlier this year.,As a result ...
... Exchange Symbol: AKL, MONTREAL, Dec. 20 /PRNewswire-FirstCall/ ... company focused on developing therapies for the,inhalation and ... market,conditions, particularly in the small and micro-cap sector, ... initiative. The Company is currently,contemplating other financing options. ...
... Data Show PROMACTA Significantly Raised Platelet Counts and,Lowered ... Treatment of,Patients with Chronic Idiopathic Thrombocytopenic Purpura (ITP), ... GSK ; London) today announced the submission ... States Food and Drug Administration,(FDA) for approval to ...
Cached Medicine News:Health News:MedImmune Expands Scientific and Engineering Leadership 2Health News:MedImmune Expands Scientific and Engineering Leadership 3Health News:MedImmune Expands Scientific and Engineering Leadership 4Health News:MedImmune Expands Scientific and Engineering Leadership 5Health News:Mental health linked to amputation risk in diabetic veterans 2Health News:Uninsured More Likely to Die From Cancer Following Diagnosis 2Health News:Uninsured More Likely to Die From Cancer Following Diagnosis 3Health News:Uninsured More Likely to Die From Cancer Following Diagnosis 4Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 2Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 3Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 4Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 5Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 6Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 7Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 8Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 9Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 10Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 11Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 12Health News:Akela Pharma provides corporate update 2Health News:GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder 2Health News:GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder 3Health News:GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder 4Health News:GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder 5
Porous foundation 440 series....
A cementless femoral stem that promotes bone in-growth and reduces thigh pain....
The cemented hip joint prosthesis system....
The uncemented hip joint prosthesis system...
Medicine Products: